Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

JCO Precis Oncol. 2022 Jun;6:e2100525. doi: 10.1200/PO.21.00525.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines
  • Humans
  • Lactams
  • Lactams, Macrocyclic
  • Lymphoma, Large-Cell, Anaplastic* / drug therapy
  • Neoplasm, Residual
  • Pyrazoles / therapeutic use

Substances

  • Aminopyridines
  • Lactams
  • Lactams, Macrocyclic
  • Pyrazoles
  • lorlatinib